Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
:AKBA
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 15.04%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call demonstrates strong early success with Vafseo's launch, exceeding expectations and showing promising trends in prescriptions and financials. While there are concerns about potential generic competition for Auryxia and slower integration with large dialysis organizations, the overall performance and future prospects are encouraging.Company Guidance
During Akebia's First Quarter 2025 financial results call, the company exceeded its US net product revenue guidance for Vafseo, reporting $12 million compared to the expected $10-$11 million. The call highlighted the strong performance in Vafseo's launch, with US net product revenue surpassing expectations and total revenues reaching $57.3 million, up from $32.6 million in the same period last year. The company's Chief Commercial Officer, Nick Grund, reported a 25% increase in the number of prescribers, ending the quarter with more than 640 prescribers and prescriptions per provider growing from nearly eight to approximately 12 by the end of March. They observed a 75% enrollment progress in the VOICE study targeting 2,200 subjects, and plans are on track to initiate the Phase III VALOR trial for non-dialysis patients by the second half of 2025. The company also maintained a solid financial position with $113.4 million in cash and cash equivalents and expressed confidence in achieving profitability based on the current operating plan.Strong Vafseo Launch
Vafseo's US net product revenues reached $12 million, exceeding the guidance of $10 million to $11 million. The launch is described as one of the strongest in the dialysis market, with nearly 100% coverage from commercial contracts with dialysis organizations.
Increased Prescriber Base
The number of prescribers increased by nearly 25% compared to February, ending the quarter with over 640 prescribers.
Positive Refill and Prescription Trends
Refills constituted about one third of all prescriptions in Q1, indicating patient retention. Prescriptions per provider increased to approximately 12 from nearly eight.
Financial Performance
Total revenues increased to $57.3 million in Q1 2025 from $32.6 million in Q1 2024, driven by Vafseo and a 43% increase in Auryxia sales.
Reduced Cost of Goods Sold
Cost of goods sold decreased to $7.6 million from $11.6 million despite higher sales, due to the elimination of a $9 million non-cash amortization charge.
Strong Cash Position
The company ended Q1 with $113.4 million in cash and cash equivalents, bolstered by a public offering raising over $46 million.
Progress in Clinical Studies
The VOICE study is 75% enrolled, targeting 2200 subjects, and the Phase III VALOR trial for non-dialysis patients is on track to begin in the second half of 2025.
AKBA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AKBA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $2.46 | $2.62 | +6.50% |
Mar 13, 2025 | $1.93 | $1.69 | -12.44% |
Nov 07, 2024 | $2.00 | $1.86 | -7.00% |
Aug 08, 2024 | $1.11 | $1.19 | +7.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics (AKBA) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Akebia Therapeutics (AKBA) earnings time?
Akebia Therapeutics (AKBA) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBA EPS forecast?
AKBA EPS forecast for the fiscal quarter 2025 (Q2) is -0.02.